What is the EVOGUARD study?
The purpose of the Evoguard study is to assess the effectiveness of EVO100 vaginal gel in preventing a Chlamydia or Gonorrhea infection, and to evaluate its safety (including your perception of how any side effects impact you) over approximately 16 weeks of treatment. Participants will earn up to $700 compensation.
What about Chlamydia and Gonorrea?
Chlamydia and Gonorrhea are both common sexually transmitted infections (STIs), spread from person-to-person, through sexual contact.
Chlamydia remains the most frequently reported infectious disease in the United States (US).
This can be passed from person-to-person through vaginal, oral, or anal sex.
Symptoms last for a few weeks, while some people may not have any symptoms at all., symptoms include:
• Burning pain during urination
• Abnormal vaginal or penile discharge
• Abnormal rectal discharge
• Bleeding from the rectum
The symptoms of Chlamydia and Gonorrhea share a number of similarities. Many doctors will treat both infections at once, since it is common that they can occur at the same time. These infections, especially when untreated, can result in serious consequences including pelvic inflammatory disease (PID), scarring, chronic pelvic pain, ectopic pregnancy and infertility. Currently, the only options available for prevention of Chlamydia and Gonorrhea infection are consistent and correct use of condoms or abstaining from sexual activity.